SEC Form 4 · accession 0000911916-16-000441
CoLucid Pharmaceuticals, Inc. · CLCD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas P. Mathers
Officer — Chief Executive Officer · Director
Period of report
Mar 4, 2016
Accepted (ET)
Mar 7, 2016 · 3:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348649
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 4, 2016 | A | 83,000 | $0.00 | A | 210,960 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $6.75 | Mar 4, 2016 | A | 83,000 | A | — | Mar 4, 2026 | Common Stock | 83,000 | 83,000 | D |
Explanation of responses
- F1On March 4, 2016, the reporting person was granted 83,000 restricted stock units, vesting in a series of 48 successive equal monthly installments with the first monthly installment vesting on the grant date and the future installments vesting on the first day of each calendar month. The restricted stock units may only be settled in shares of common stock on a one-for-one basis.
- F2Options vest in a series of 48 successive equal monthly installments with the first monthly installment vesting on the grant date and the future installments vesting on the first day of each calendar month.